Atai Beckley announces presentations at ACNP

AtaiBeckley announced its participation in the 64th Annual Meeting of the American College of Neuropsychopharmacology, ACNP, which took place on January 12 – 15, 2026 in Nassau, The Bahamas. The Company presented new clinical and preclinical data supporting its development of transformative mental health therapies in two poster presentations and a Hot Topic Presentation. Poster titled ‘Rapid Antidepressant Effect of Intranasal BPL-003 in Treatment-Resistant Depression: A Phase 2b Double-Blind Study’ showed a single 8 mg or 12 mg dose of BPL-003 resulted in a significant and sustained antidepressant effect compared with a 0.3 mg sub-perceptual dose control at all timepoints in the study, and that both active dose levels were well-tolerated. Preclinical poster titled ‘The Pharmacological, Pharmacokinetic and Potential Neuroplasticity-Related Profile of 5-MeO-DMT, a 5-HT Receptor Agonist for the Treatment of Mood Disorders’ investigated in vitro binding, in vivo pharmacokinetics, efficacy and potential mechanism of action of 5-MeO-DMT preclinically. The findings support effects of 5-MeO-DMT that are potentially relevant to its therapeutic use for the treatment of mood disorders, and highlight therapeutic approaches for targeting neuroplasticity alterations thought to be implicated in individuals with mood disorders.